+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Vaccine Market - Global Forecast 2026-2032- Product Image
Oral Vaccine Market - Global Forecast 2026-2032- Product Image
Sale

Oral Vaccine Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4995182
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Vaccine Market is projected to reach USD 4.48 Billion in 2026. It is expected to continue growing at a CAGR of 8.43%, reaching USD 7.34 Billion by 2032.

The oral vaccine market sits at the intersection of infectious disease control, mucosal immunology, outbreak preparedness, and scalable immunization delivery. Oral vaccines are valued because they can stimulate immune responses at mucosal surfaces, simplify administration compared with injectable products, and support mass vaccination campaigns in settings where trained vaccinators, sterile injection supplies, and clinic-based delivery capacity are constrained.

Commercial and public health demand is anchored by established products such as oral polio vaccine, rotavirus vaccines, oral cholera vaccines, and oral typhoid vaccines. The category is also gaining strategic attention as governments, multilateral buyers, and manufacturers pursue thermostable formulations, improved supply security, and next-generation platforms that can reduce logistical friction across routine immunization, travel medicine, and emergency response.

Transformative Shifts in the Oral Vaccine Landscape

The oral vaccine landscape is shifting from product availability toward program resilience, equity of access, and rapid outbreak response. Global experience with oral polio vaccine demonstrates the value of easy administration at scale, while also showing the importance of high coverage, surveillance, and careful strain selection to reduce vaccine-derived poliovirus risk in under-immunized communities.

Rotavirus and cholera vaccination programs are accelerating the focus on affordability, cold-chain optimization, and supply diversification. The global cholera resurgence reported by the World Health Organization has intensified demand for oral cholera vaccine stockpiles, while rotavirus vaccine adoption in national immunization schedules continues to support pediatric disease prevention in low- and middle-income countries.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across oral vaccine discovery, development, manufacturing, and post-market monitoring. In research, AI-enabled modeling can help prioritize antigens, predict immune epitopes, assess strain evolution, and support formulation screening for stability and mucosal delivery performance. These applications are most valuable when paired with validated laboratory assays, clinical evidence, and regulatory-grade quality systems.

AI also strengthens demand forecasting, pharmacovigilance signal detection, cold-chain planning, and outbreak allocation decisions. For oral vaccines used in emergency campaigns, such as oral cholera vaccine and oral polio vaccine, predictive analytics can help public health agencies align stockpiles, distribution timing, and population targeting with epidemiological risk while maintaining human oversight and transparent governance.

Key Regional Insights for Oral Vaccines

Asia-Pacific is a major growth arena for oral vaccines because of large birth cohorts, high population density, and continued investment in routine immunization. India and China influence global supply and demand through domestic manufacturing scale, national immunization priorities, and expanding biotechnology capabilities, while Southeast Asian markets benefit from donor-supported vaccination, regional disease surveillance, and continued focus on rotavirus, cholera, typhoid, and polio prevention.

North America and Europe are characterized by mature regulatory systems, travel vaccine demand, advanced pharmacovigilance, and strong clinical development infrastructure. In North America, oral vaccine demand is shaped by traveler protection, outbreak readiness, and evidence-based immunization guidance, while Europe supports clinical quality standards, centralized regulatory coordination, and public-sector procurement discipline. Latin America remains important for rotavirus vaccine uptake, outbreak preparedness, and public-sector procurement, supported by regional experience in immunization campaigns and diarrheal disease control. The Middle East increasingly links immunization planning with humanitarian response, migration, pilgrimage health security, and regional cold-chain modernization. Africa represents one of the most consequential demand centers for oral polio vaccine, rotavirus vaccines, and oral cholera vaccines due to disease burden, emergency campaigns, cross-border transmission risks, and the strategic role of WHO-, UNICEF-, and Gavi-supported programs.

Key Group Insights Across Major Economic Blocs

ASEAN markets are advancing oral vaccine access through immunization strengthening, local regulatory cooperation, and growing attention to cholera, typhoid, and pediatric diarrheal disease prevention. The GCC combines high-income health systems with travel, migration, and pilgrimage-related health security needs, supporting demand for targeted oral vaccine preparedness, traveler protection, and emergency response coordination.

The European Union and G7 shape standards for clinical evidence, vaccine safety monitoring, financing, procurement quality, and manufacturing oversight, reinforcing the role of transparent regulatory pathways and post-market surveillance in oral vaccine adoption. NATO countries increasingly view vaccine supply security, stockpile planning, and resilient logistics as part of broader health security and civil preparedness. BRICS nations are especially influential because China, India, Brazil, Russia, and South Africa combine large populations, public procurement power, expanding vaccine manufacturing capacity, and technology-transfer priorities that can affect global oral vaccine availability and access.

Key Country Insights in Leading Oral Vaccine Markets

The United States and Canada emphasize stringent regulatory review, traveler vaccination, clinical innovation, immunization safety monitoring, and outbreak readiness, while Mexico and Brazil support regional demand through public immunization programs, pediatric vaccine adoption, and disease surveillance. In Europe, the United Kingdom, Germany, France, Italy, and Spain contribute advanced research capacity, procurement discipline, clinical trial infrastructure, and regulatory alignment through European systems, while Russia maintains domestic vaccine production capabilities and strategic immunization programs.

China and India are central to oral vaccine manufacturing, scale-up economics, and national disease control priorities, with both countries playing influential roles in pediatric immunization, outbreak response, and supply continuity. Japan, Australia, and South Korea add high-quality clinical research, advanced cold-chain infrastructure, strong regulatory oversight, and regional health security leadership, strengthening Asia-Pacific’s role in next-generation oral vaccine development and deployment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient supply chains, diversified antigen and formulation pipelines, and manufacturing partnerships that can respond to both routine immunization demand and emergency outbreak surges. Investments in thermostable oral vaccine technologies, packaging efficiency, strain surveillance, and lower-cost production can improve access in markets where cold-chain limitations and campaign logistics remain persistent barriers.

Organizations should also strengthen evidence generation for mucosal immunity, duration of protection, safety in target age groups, co-administration with routine vaccines, and real-world effectiveness. Strategic alignment with WHO prequalification pathways, national immunization technical advisory groups, donor procurement requirements, regulatory quality expectations, and digital pharmacovigilance systems will be essential for credible market entry and sustainable adoption.

Research Methodology

This executive summary is developed through a structured synthesis of verified public health, regulatory, and market-relevant sources, including WHO guidance, UNICEF and Gavi procurement context, national immunization program practices, regulatory agency frameworks, peer-reviewed evidence, and established vaccine safety principles. The analysis emphasizes factual signals rather than speculative market claims, sizing assumptions, or forecast-based conclusions.

The methodology evaluates product categories, disease burden drivers, regional immunization dynamics, procurement mechanisms, regulatory pathways, technology trends, and supply-chain constraints. Insights are cross-checked for consistency across public health priorities, commercial feasibility, and operational realities affecting oral polio, rotavirus, cholera, and typhoid vaccine deployment.

Conclusion

Oral vaccines remain a critical segment of global immunization because they combine public health impact with operational simplicity. Their value is most visible in pediatric disease prevention, mass campaigns, outbreak response, travel medicine, and settings where injectable delivery is harder to sustain at scale.

The future of the oral vaccine market will be shaped by supply reliability, next-generation mucosal delivery science, AI-supported development, and policy alignment across countries and procurement bodies. Organizations that invest in evidence, affordability, manufacturing resilience, quality systems, and equitable access will be best positioned to support this evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oral Vaccine Market, by Vaccine Type
7.1. Introduction
7.2. Conjugate Vaccines
7.3. Inactivated Vaccines
7.3.1. Whole-Cell Inactivated
7.3.2. Toxoid-Based
7.4. Live Attenuated Vaccines
7.4.1. Bacterial
7.4.2. Viral
7.5. Mrna Vaccines
7.6. Subunit Vaccines
7.6.1. Protein Subunit
7.6.2. Polysaccharide Subunit
8. Oral Vaccine Market, by Disease Indication
8.1. Introduction
8.2. Influenza
8.3. Norovirus
8.4. Poliovirus
8.5. Rotavirus
9. Oral Vaccine Market, by Age Group
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Oral Vaccine Market, by Distribution Channel
10.1. Introduction
10.2. Online
10.3. Offline
11. Oral Vaccine Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Oral Vaccine Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Oral Vaccine Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AstraZeneca plc
15.2. Bharat Biotech International Limited
15.3. Biological E. Limited
15.4. Cadila Healthcare Limited
15.5. Emergent BioSolutions Inc.
15.6. GlaxoSmithKline plc
15.7. Indian Immunologicals Limited
15.8. Johnson & Johnson
15.9. Merck & Co., Inc.
15.10. Novavax, Inc.
15.11. Oramed Pharmaceuticals Inc.
15.12. Panacea Biotec Limited
15.13. Pfizer Inc.
15.14. Sanofi S.A.
15.15. Serum Institute of India Private Limited
15.16. Valneva SE
15.17. Vaxart, Inc.
List of Figures
FIGURE 1. GLOBAL ORAL VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ORAL VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ORAL VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ORAL VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ORAL VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONJUGATE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONJUGATE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL WHOLE-CELL INACTIVATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL WHOLE-CELL INACTIVATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL WHOLE-CELL INACTIVATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TOXOID-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TOXOID-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TOXOID-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL VIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MRNA VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SUBUNIT VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SUBUNIT VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NOROVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NOROVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NOROVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL POLIOVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL POLIOVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL POLIOVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ROTAVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ROTAVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ROTAVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 76. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 79. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 80. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 82. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 84. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 86. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 87. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 88. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 89. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 92. EUROPE ORAL VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 94. EUROPE ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 95. EUROPE ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 96. EUROPE ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 97. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 99. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 100. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 102. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 103. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 104. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 105. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 106. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 108. AFRICA ORAL VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 110. AFRICA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 111. AFRICA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 112. AFRICA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 113. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 114. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 115. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. ASEAN ORAL VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 119. ASEAN ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 120. ASEAN ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 121. ASEAN ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 122. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 123. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 124. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. GCC ORAL VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 127. GCC ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 128. GCC ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 129. GCC ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 130. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 131. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 132. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. BRICS ORAL VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 143. BRICS ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 144. BRICS ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 145. BRICS ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 146. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 147. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 148. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. G7 ORAL VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 151. G7 ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 152. G7 ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 153. G7 ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 154. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 155. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 156. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 157. NATO ORAL VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 159. NATO ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 160. NATO ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 161. NATO ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 162. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 163. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 164. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. UNITED STATES ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 167. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 168. UNITED STATES ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 171. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 172. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. CANADA ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 175. CANADA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 176. CANADA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 177. CANADA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 178. CANADA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 179. CANADA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 180. CANADA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 181. CANADA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. MEXICO ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. MEXICO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 184. MEXICO ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 185. MEXICO ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 186. MEXICO ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 187. MEXICO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 188. MEXICO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 189. MEXICO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. BRAZIL ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 191. BRAZIL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 192. BRAZIL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 193. BRAZIL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 194. BRAZIL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 195. BRAZIL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 196. BRAZIL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. BRAZIL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. UNITED KINGDOM ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 206. GERMANY ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. GERMANY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 208. GERMANY ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 209. GERMANY ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 210. GERMANY ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 211. GERMANY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 212. GERMANY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 213. GERMANY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. FRANCE ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. FRANCE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 216. FRANCE ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 217. FRANCE ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 218. FRANCE ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 219. FRANCE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 220. FRANCE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 221. FRANCE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. RUSSIA ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. RUSSIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 224. RUSSIA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 225. RUSSIA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 226. RUSSIA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 227. RUSSIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 228. RUSSIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 230. ITALY ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. ITALY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 232. ITALY ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 233. ITALY ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 234. ITALY ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 235. ITALY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 236. ITALY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 237. ITALY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 238. SPAIN ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. SPAIN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 240. SPAIN ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 241. SPAIN ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 242. SPAIN ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 243. SPAIN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 244. SPAIN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 245. SPAIN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. CHINA ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 248. CHINA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 249. CHINA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 250. CHINA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 251. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 252. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 253. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. INDIA ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. INDIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 256. INDIA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 257. INDIA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 258. INDIA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 259. INDIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 260. INDIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 261. INDIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. JAPAN ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. JAPAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 264. JAPAN ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 265. JAPAN ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 266. JAPAN ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 267. JAPAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 268. JAPAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 269. JAPAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. AUSTRALIA ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. AUSTRALIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 272. AUSTRALIA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 273. AUSTRALIA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 275. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 276. AUSTRALIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 277. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. SOUTH KOREA ORAL VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 280. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2017-2032 (USD MILLION)
TABLE 281. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2017-2032 (USD MILLION)
TABLE 282. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2017-2032 (USD MILLION)
TABLE 283. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 284. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 285. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. GLOBAL ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 287. GLOBAL ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • Biological E. Limited
  • Cadila Healthcare Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Indian Immunologicals Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Oramed Pharmaceuticals Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Private Limited
  • Valneva SE
  • Vaxart, Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.48 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.34 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Oral Vaccine Market Report 2026 - Product Image

Oral Vaccine Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Therapeutic Proteins and Oral Vaccines Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Therapeutic Proteins and Oral Vaccines Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
2025 Global Forecast for Therapeutic Proteins and Oral Vaccines Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Therapeutic Proteins and Oral Vaccines Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
2025 Global Forecast for Oral Vaccines Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Oral Vaccines Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Multivalent Oral Rotavirus Vaccine Market - Global Forecast 2026-2032 - Product Image

Multivalent Oral Rotavirus Vaccine Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From

About the Oral Vaccine Market

The Oral Vaccine market is a subset of the larger Vaccines market, which is focused on the development and distribution of vaccines to prevent and treat infectious diseases. Oral Vaccines are administered orally, rather than through injection, and are typically used to protect against gastrointestinal infections. These vaccines are often used in developing countries, where access to injection-based vaccines may be limited. Oral Vaccines are also used in certain circumstances where injection-based vaccines may not be suitable, such as in the elderly or immunocompromised individuals. Oral Vaccines are typically composed of weakened or killed pathogens, which stimulate the body’s immune system to produce antibodies against the disease. These vaccines are typically administered in multiple doses, and may require booster shots to maintain immunity. Some companies in the Oral Vaccine market include GlaxoSmithKline, Merck, Sanofi, Pfizer, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.